October 26, 2009
Icosagen Cell Factory signed a contract with Sanofi Pasteur
Icosagen Cell Factory OÜ and Sanofi Pasteur, the vaccines division of sanofi-aventis Group, signed an agreement pursuant to which a technology licence to Sanofi Pasteur was granted to evaluate the QMCF technology with the option to proceed with a license for research activities.
Proceed »September 03, 2009
Icosagen Cell Factory granted a license to Bayer HealthCare
Icosagen Cell Factory OÜ and Bayer HealthCare extended an existing agreement, pursuant to which a non-exclusive licence to use QMCF technology for research activities was granted to Bayer HealthCare. Proceed »September 03, 2009
Enterprise Estonia issued a grant to Icosagen Cell Factory
Icosagen Cell Factory has received an applied reseach grant from Enterprise Estonia to develop a technology for cell-based assay construction that utilises elements from QMCF Technology proprietary to the company. The reseach grant is MEUR 1. The total amount of the R&D project is MEUR 1.5. The project starts on 1 September and lasts for a period of two years.
Proceed »May 22, 2009
Icosagen Cell Factory has been granted a European patent
Icosagen
Cell Factory (previously Quattromed Cell Factory) has been granted a patent relating
to its QMCF Technology. The European Patent Office announced on 25 March 2009
that it intends to grant European patent application No 06706887.4 with the
title “Vectors, cell lines and their use in obtaining extended episomal
maintenance replication of hybrid plasmids and expression of gene products”
with European patent number 1851319.
Proceed »
April 09, 2009
Icosagen Group has a new homepage
As of 9 April 2009, the Icosagen Group has a new homepage at the address www.icosagen.ee
Proceed »
